



EXPERIENCES USING GLP-1 RECEPTOR AGONISTS IN PEOPLE WITH DEMENTIA

ABOUT THE RESEARCH

Researchers at the University of Canberra are conducting a study to understand how GLP-1 receptor agonist medications (such as Ozempic, Trulicity, Mounjaro, or Saxenda) may affect appetite and eating in people with dementia. We want to hear directly from people with dementia and their care partners about their experiences.



PARTICIPANT INVOLVEMENT

If you choose to take part, you will be invited to a face-to-face interview at the University of Canberra Hospital (or online if preferred). The interview will take approximately 30-45 minutes and will involve questions about your appetite, eating habits, and meals since starting your GLP-1 medication. *A care partner is welcome to attend and contribute.*

Who can take part?

- Aged 50 years or over
- Living with dementia (mild to moderate)
- Currently taking a GLP-1 medication for at least four weeks
- Living at home or a retirement village in the ACT or NSW
- Able to participate in an interview in English or Chinese

REGISTER INTEREST

Phone:

- Nathan D'Cunha: 02 6206 8585

Email:

- Hin Kan Sin: u3325371@uni.canberra.edu.au
- Kerist Klekner: u3246378@uni.canberra.edu.au

